I-02 Mona Alameddine Population Pharmacokinetic Analysis and Effects of Raltegravir In HIV positive and Healthy Individuals Wednesday 10:15-11:45 |
I-03 Sarah Alghanem Development of a Tobramycin Dosage Adjustment Nomogram for Patients with Cystic Fibrosis Wednesday 10:15-11:45 |
I-16 Julie Bertrand Extensive Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients Wednesday 10:15-11:45 |
I-30 Margreke Brill Cefazolin pharmacokinetics in morbidly obese patients following a prophylactic dose during weight reducing surgery. Wednesday 10:15-11:45 |
I-39 Georgia Charkoftaki Pharmacokinetics of doripenem in cerebrospinal fluid Wednesday 10:15-11:45 |
I-46 Christine Xu Population Pharmacokinetics (PPK) and Pharmacokinetic-Pharmacodynamic (PK/PD) of Vicriviroc in Treatment Naive HIV Wednesday 10:15-11:45 |
I-60 Paolo Denti Population PK of Isoniazid in South African Adults. Wednesday 10:15-11:45 |
II-17 Monika Frank Integrated Population Pharmacokinetic Model Development of Nevirapine for Mothers and Newborns including Healthy Male Volunteer Data Wednesday 14:55-16:10 |
II-22 Maria Garrido Population Pharmacokinetics/Pharmacodynamics of Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in SOT Patients Infected with CMV Wednesday 14:55-16:10 |
II-27 Sylvain Goutelle Comparison of Four Renal Function Estimator-Based Models for the Prediction of Gentamicin Concentrations in Geriatric Patients by Use of Nonparametric Population Approach Wednesday 14:55-16:10 |
II-35 Monia Guidi Population Pharmacokinetics of Nevirapine in HIV-positive Patients Wednesday 14:55-16:10 |
II-43 Richard Höglund Population modelling of the pharmacokinetics of a mefloquine-artesunate treatment at the Thai-Myanmar border Wednesday 14:55-16:10 |
II-46 Arantxa Isla Population Pharmacokinetics of Cefoxitin as a Prophylactic Antimicrobial Agent Wednesday 14:55-16:10 |
II-60 Dalia Khachman Optimising ciprofloxacin dosing in intensive care patients based on pharmacodynamic target attainment Wednesday 14:55-16:10 |
II-61 David Khan PKPD-modeling of time-kill curves from E. coli mutants exposed to ciprofloxacin Wednesday 14:55-16:10 |
III-05 Ryuji Kubota A Novel Framework of Long-term Prediction of integrase inhibitors for treatment naïve patients Thursday 09:50-11:05 |
III-36 Elisabet Nielsen PK/PD Indices of Antibiotics Predicted by Mechanism-Based PKPD Models Thursday 09:50-11:05 |
III-63 Dinko Rekic Bilirubin - a biomarker of atazanavir exposure in HIV/AIDS patients Thursday 09:50-11:05 |
IV-04 Andre Schäftlein Comparison of elimination and absorption pharmacokinetics of linezolid in cystic fibrosis patients by three nonlinear models Thursday 15:05-16:20 |
IV-09 Ivy Song Applications of Population Pharmacokinetic Modeling during Phase2B to Support the Clinical Development of Dolutegravir (DTG, S/GSK1349572) Thursday 15:05-16:20 |
IV-12 Joe Standing Methods for Optimising Neonatal Antimicrobial Use: Time- and Concentration-Dependent Agents Thursday 15:05-16:20 |
IV-16 Elin Svensson Mega-model of nevirapine population pharmacokinetics Thursday 15:05-16:20 |
IV-17 Svetlana Vinogradova Applying of population PK-PD methods to analysis of viral dynamics of HIV/HCV-Coinfected Sustained Virological Responders and Nonresponders treated with PEG-IFN Thursday 15:05-16:20 |
IV-18 Ami Fazlin Syed Mohamed Pharmacokinetic-Pharmacodynamic Modelling of Pre-existing and Emerging Resistance of Pseudomonas aeruginosa to Colistin Thursday 15:05-16:20 |
IV-34 Marta Valle Effect of Ritonavir Concentrations on Atazanavir Pharmacokinetics: Population Pharmacokinetic Analysis Thursday 15:05-16:20 |
IV-35 Georgia Valsami Assessment of dosage regimens of tigecycline in hospitalised patients Thursday 15:05-16:20 |
IV-38 Jan-Stefan van der Walt The effect of nevirapine-based antiretroviral therapy on the population pharmacokinetics of artemether and dihydroartemesinin in HIV-infected adults Thursday 15:05-16:20 |
IV-42 Max von Kleist A Mathematical Modelling Framework to Assess the Impact of Nevirapine-based Prophylaxis on vertical HIV Transmission Thursday 15:05-16:20 |
IV-45 Toshihiro Wajima Pharmacokinetic/pharmacodynamic Modeling and Long-term Simulation of Dolutegravir (DTG, S/GSK1349572) in Integrase Resistant Patients with a Simple Viral Dynamic Model Thursday 15:05-16:20 |
IV-54 Hongmei Xu Mechanism-based Modelling of the Antagonism between Polymyxin B and Levofloxacin against Pseudomonas aeruginosa using Mono- and Combination Therapy Thursday 15:05-16:20 |
IV-57 James Yates Population PK/PD modelling of AZD9773 in patients with severe sepsis. Thursday 15:05-16:20 |
IV-62 Chao Zhang Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Adults Thursday 15:05-16:20 |
IV-66 Simbarashe Peter Zvada Population Pharmacokinetics of Isoniazid in Children with Pulmonary Tuberculosis Thursday 15:05-16:20 |